- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Xalkori
Synonyms :
crizotinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor;
250
mg
Oral
twice a day
Continue the therapy until disease progression or unacceptable effects occur.
280
mg
Orally
twice a day
Capsule
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the effect of flibanserin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in the effect of crizotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in levels of lomitapide by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in the QTC interval
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib can impact the hepatic/intestinal enzyme CYP3A4 metabolism, leading to an elevation in the level or potency of intranasal midazolam
it may enhance the qtc interval when combined with lofexidine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of crizotinib
midostaurin and crizotinib, when used simultaneously, increase the QTc level
midostaurin and crizotinib, when used simultaneously, increase the QTc level
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be an increase in QTC interval
when both drugs are combined, there may be an increase in QTC interval
it may enhance the metabolism when combined with oxcarbazepine
Combining tegafur with crizotinib can reduce tegafur’s metabolism
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
QTc interval is increased both by lenvatinib and crizotinib
the effect of crizotinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, both increase the QTC interval
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may enhance serum level and toxicity of docetaxel
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
when both drugs are combined, there may be an increase in QTC interval
when both drugs are combined, there may be an increase in QTC interval
Adverse drug reactions:
Frequency defined
>10%
Upper respiratory infection
Neutropenia
lymphopenia
leukopenia
Anemia
Dysgeusia
dizziness
balance disorder
dizziness
dizziness postural
presyncope
neuropathy
0.1-1%:
QT interval prolongation
Cardiac failure congestive
ejection fraction decreased
left ventricular failure
pulmonary edema
Syncope
Hepatic failure
increased gamma-glutamyl transferase
Febrile neutropenia
Pulmonary embolism
interstitial lung disease
Renal cyst
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: crizotinib (Rx)
Pronounced: kriz-OH-ti-nib
Why do we use crizotinib?
crizotinib is an anticancer drug used to treat non-small cell lung cancer (NSCLC) and inhibits the growth and spread of cancer cells.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
